Testing a blood sample to help diagnose liposarcoma
Tests whether a blood sample can help diagnose liposarcoma in adults.
Plain-language title generated from the registry record
Registry title: Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Key facts
- Where
- Montpellier, FranceSee the site
Where in France
- Institut du Cancer de Montpellier - Val d'AurelleMontpellier, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut du Cancer de Montpellier - Val d'Aurelle
- Trial code
- NCT04224064
- Record updated
- 12 February 2025
- Original description
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.Read full original descriptionShow less
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Inclusion: Men/women older than 18 years old,; Surgery for :; Localized WD-LPS and DD-LPS, and/or; WD-LPS or DD-LPS local relapse, and/or; WD-LPS or DD-LPS distant relapse and/or; Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent; Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort.
Exclusion: Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma; Pregnancy and/or feeding.